Xinhua Pharmaceutical (HKEx: 00719, SZSE: 000756) Gains Approval for Vonoprazan Fumarate API

Bulletin Express

2025/11/17

Shandong Xinhua Pharmaceutical Company Limited (Xinhua Pharmaceutical, HKEx: 00719, SZSE: 000756) announced that it has received approval from the National Medical Products Administration for its domestically produced Vonoprazan Fumarate active pharmaceutical ingredient. The product is primarily indicated for the treatment of reflux esophagitis and is listed as a Category B product in the National Drug Catalogue for Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance (2025).

According to the announcement, sales of Vonoprazan Fumarate-related preparations in China’s public medical institutions reached approximately RMB 825 million in 2024. The new approval is expected to enrich the company’s product line and strengthen its competitiveness, although the pharmaceutical sales business remains vulnerable to policy changes, market fluctuations, and procurement processes. The company affirms that all information in the announcement is accurate and complete.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1193148741"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1193148741\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1193148741?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-17 17:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1193148741","market":"us","top_or_hot":-1,"title":"Xinhua Pharmaceutical (HKEx: 00719, SZSE: 000756) Gains Approval for Vonoprazan Fumarate API","media":"Bulletin Express","content":"<p>Shandong Xinhua Pharmaceutical Company Limited (Xinhua Pharmaceutical, HKEx: 00719, SZSE: 000756) announced that it has received approval from the National Medical Products Administration for its domestically produced Vonoprazan Fumarate active pharmaceutical ingredient. The product is primarily indicated for the treatment of reflux esophagitis and is listed as a Category B product in the National Drug Catalogue for Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance (2025).</p>\n<p>According to the announcement, sales of Vonoprazan Fumarate-related preparations in China’s public medical institutions reached approximately RMB 825 million in 2024. The new approval is expected to enrich the company’s product line and strengthen its competitiveness, although the pharmaceutical sales business remains vulnerable to policy changes, market fluctuations, and procurement processes. The company affirms that all information in the announcement is accurate and complete.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xinhua Pharmaceutical (HKEx: 00719, SZSE: 000756) Gains Approval for Vonoprazan Fumarate API</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXinhua Pharmaceutical (HKEx: 00719, SZSE: 000756) Gains Approval for Vonoprazan Fumarate API\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2025-11-17 17:02</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shandong Xinhua Pharmaceutical Company Limited (Xinhua Pharmaceutical, HKEx: 00719, SZSE: 000756) announced that it has received approval from the National Medical Products Administration for its domestically produced Vonoprazan Fumarate active pharmaceutical ingredient. The product is primarily indicated for the treatment of reflux esophagitis and is listed as a Category B product in the National Drug Catalogue for Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance (2025).</p>\n<p>According to the announcement, sales of Vonoprazan Fumarate-related preparations in China’s public medical institutions reached approximately RMB 825 million in 2024. The new approval is expected to enrich the company’s product line and strengthen its competitiveness, although the pharmaceutical sales business remains vulnerable to policy changes, market fluctuations, and procurement processes. The company affirms that all information in the announcement is accurate and complete.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00719","symbol_name":"山東新華製藥股份","start_time":0,"source_url":"","article_id":"1193148741","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1193148741","pubTimestamp":1763370173,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shandong Xinhua Pharmaceutical Company Limited (Xinhua Pharmaceutical, HKEx: 00719, SZSE: 000756) announced that it has received approval from the National Medical Products Administration for its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00719":"山东新华制药股份"},"translate_title":"新华制药（港交所：00719，深交所：000756）富马酸沃诺拉赞原料药获批","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00719":1},"content_text":"Shandong Xinhua Pharmaceutical Company Limited (Xinhua Pharmaceutical, HKEx: 00719, SZSE: 000756) announced that it has received approval from the National Medical Products Administration for its domestically produced Vonoprazan Fumarate active pharmaceutical ingredient. The product is primarily indicated for the treatment of reflux esophagitis and is listed as a Category B product in the National Drug Catalogue for Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance (2025).\nAccording to the announcement, sales of Vonoprazan Fumarate-related preparations in China’s public medical institutions reached approximately RMB 825 million in 2024. The new approval is expected to enrich the company’s product line and strengthen its competitiveness, although the pharmaceutical sales business remains vulnerable to policy changes, market fluctuations, and procurement processes. The company affirms that all information in the announcement is accurate and complete.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}